Previous 10 | Next 10 |
Merus N.V. ( NASDAQ: MRUS ) lost ~10% on Wednesday after the Dutch biotech updated initial in-human data for its cancer therapy MCLA-129 from a Phase 1/2 trial involving patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. The readout inclu...
- MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels - Initial recommended phase 2 dose 1500 mg every two weeks; expansion cohorts enroll...
– MCLA-129 observed to be well tolerated with preliminary evidence of anti-tumor activity during dose escalation phase – Initial recommended phase two dose set at 1500 mg with dose expansion ongoing – Poster presentation with additional data at ENA available o...
The following slide deck was published by Merus N.V. in conjunction with this event. For further details see: Merus NV (MRUS) Investor Presentation- Slideshow
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecifi...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., P...
Merus press release ( NASDAQ: MRUS ): Q2 GAAP EPS of -$0.13 beats by $0.49 . Revenue of $12.68M (+2.4% Y/Y) beats by $2.23M . For further details see: Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
The shares of Dutch biotech Merus N.V. ( NASDAQ: MRUS ) added ~8% on Tuesday after Stifel initiated its coverage on the stock with a Buy recommendation as the analysts weighed in on the potential of thee of the company’s bispecific antibody candidates. Bispecific ...
We conclude our roundtable series with Biotech and Healthcare coverage. Seven of our Marketplace contributors give their analysis and share one top idea. Look for more roundtables and analysis this summer from our community of 180+ Marketpalce services. ~ By Tim Murphy, Ma...
Shares have risen by 40% since my 2020 ROTY update, but have lost a third of their value in 2022. I provide a recap of our thesis on this promising platform technology play in the oncology space. Data for Zeno in NRG1+ cancers at ASCO impressed with consistent ORR and clinical ben...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...